Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Wei‐Min Tong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6240-0267; OpenAlex author ID A5015323681. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. ALKBH5 in Cancer-Associated Fibroblasts Governs an Epitranscriptomic Axis That Drives Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-25-2950↗
  2. Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth. Co-author DOI 10.1016/j.canlet.2022.216040↗
  3. Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-023-01188-z↗
  4. Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1-mucin pathway. Co-author DOI 10.1038/s41556-022-00857-4↗
  5. RNA m6A Demethylase ALKBH5 Protects Against Pancreatic Ductal Adenocarcinoma via Targeting Regulators of Iron Metabolism. Co-author DOI 10.3389/fcell.2021.724282↗
  6. The effects of CYP24A1 on clinicopathological features and the prognosis of pancreatic ductal adenocarcinoma. Last author DOI 10.21037/tcr.2020.02.78↗
  7. A novel pancreatic cancer model originated from transformation of acinar cells in adult tree shrew, a primate-like animal. Co-author DOI 10.1242/dmm.038703↗
  8. The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-017-05274-4↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoding Liu · 3 shared papers, 2021–2026 · strength 0.52
  2. Zhiyong Liang · 3 shared papers, 2021–2026 · strength 0.52
  3. Huanwen Wu · 2 shared papers, 2023–2026 · strength 0.38
  4. Bohan Liu · 1 shared paper, 2026 · strength 0.22
  5. Xianglin Yin · 1 shared paper, 2026 · strength 0.22
  6. Xuqing Shi · 1 shared paper, 2026 · strength 0.22
  7. Y. Liu · 1 shared paper, 2023 · strength 0.18
  8. Jie Chen · 1 shared paper, 2023 · strength 0.18
  9. Xianlong Chen · 1 shared paper, 2023 · strength 0.18
  10. Shuangni Yu · 1 shared paper, 2023 · strength 0.18
  11. Yue Zhang · 1 shared paper, 2023 · strength 0.18
  12. Heng Ma · 1 shared paper, 2023 · strength 0.18
  13. Wei Gao · 1 shared paper, 2020 · strength 0.16
  14. Hangqi Liu · 1 shared paper, 2023 · strength 0.16
  15. Qiaofei Liu · 1 shared paper, 2023 · strength 0.16
  16. Ruiyu Li · 1 shared paper, 2023 · strength 0.16
  17. Menghua Dai · 1 shared paper, 2023 · strength 0.16
  18. Rui Huang · 1 shared paper, 2021 · strength 0.14
  19. Bo Huang · 1 shared paper, 2022 · strength 0.13
  20. Yabo Zhou · 1 shared paper, 2022 · strength 0.13
  21. Yuying Liu · 1 shared paper, 2022 · strength 0.13
  22. Jiadi Lv · 1 shared paper, 2022 · strength 0.13
  23. Qiu Tu · 1 shared paper, 2019 · strength 0.08
  24. Xintong Jia · 1 shared paper, 2019 · strength 0.08
  25. Xudong Zhao · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.